Novita Pharmaceuticals Financing
Novita Pharmaceuticals, Inc., Corporation just had published form D for $3.16 million equity financing. This is a new filing. Novita Pharmaceuticals, Inc. is expected to sell $3.16 million in this financing round. The total offering amount was $3.16 million. The private financing document was filed on 2016-11-02. The reason for the financing was: unspecified. The fundraising still has about $3.16 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Novita Pharmaceuticals is based in New York. The filler’s business is Biotechnology. The form D was signed by Christy Y Shue Chief Financial Officer. The company was incorporated more than five years ago. The filler’s address is: 1161 York Ave, Apt #8C, New York, Ny, New York, 10065. Christy Y. Shue is the related person in the form and it has address: 1161 York Avenue, Apt. #8C, New York, Ny, New York, 10065. Link to Novita Pharmaceuticals Filing: 000089706916001101.
Analysis of Novita Pharmaceuticals Offering
On average, startups in the Biotechnology sector, sell 73.77% of the total offering amount. Novita Pharmaceuticals sold 0.00% of the offering. The fundraising is still open. The average financing size for companies in the Biotechnology industry is $3.08 million. The offering was 100.00% smaller than the average of $3.08 million. Of course this should not be taken as negative. Businesses raise funds for a variety of needs and reasons. The minimum investment for this offering was set at $50552. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Novita Pharmaceuticals Also
The Form D signed by Christy Y Shue might help Novita Pharmaceuticals, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.